Oxycodone/naltrexone - Elite Pharmaceuticals

Drug Profile

Oxycodone/naltrexone - Elite Pharmaceuticals

Alternative Names: Abuse resistant oxycodone; ELI-200; ELI-201; ELI-216; Naltrexone/oxycodone - Elite Pharmaceuticals; Oxy-Nal; OxyNal™; SequestOx

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator Elite Pharmaceuticals
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Morphinans; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Preregistration Pain
  • Phase III Postoperative pain

Most Recent Events

  • 13 Mar 2017 Elite Pharmaceuticals initiates enrolment in a comparative bioavailability and bioequivalence trial of ELI 200
  • 23 Jan 2017 Elite intends to resubmit the NDA application to US FDA for ELI 200 in 2017
  • 23 Jan 2017 Elite Pharmaceuticals plans to initiate bridging studies for oxycodone/naltrexone
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top